Cas 75847-73-3 Antihypertensive Drug Enalapril For High Blood Pressure ACE Inhibitors Powder

Basic Information
Place of Origin: China
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Your demand
Delivery Time: Negotiation
Payment Terms: D/P, D/A, L/C, T/T
Supply Ability: Negotiation
Cas No: 75847-73-3 Ec No: 616-271-9
Name: Enalapril Synonyms: (S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
Molecular Formula: C20H28N2O5 Molecular Weight: 376.45
Melting Point: 142-147°C Boiling Point: 582.4±50.0°C
Solubility: Soluble In Water At 25mg/ml Density: 1.204±0.06 G/cm3
Risk Codes: N/A Safety Description: S22-24/25
High Light:

enalapril powder


antihypertensive medication enalapril


antihypertensive ace inhibitors



Enalapril Cas No 75847-73-3 API; cardiovascular and cerebrovascular; ACE inhibitors




Name Enalapril
Synonyms (S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
Molecular Formula C20H28N2O5
Molecular Weight 376.45
CAS Registry Number 75847-73-3
EINECS Number 616-271-9
Melting point 142-147°C
Boiling point 582.4±50.0°C
Solubility Soluble in water at 25mg/ml
Density 1.204±0.06 g/cm3
Safety Description S22-24/25
Risk Codes N/A


Product Description:

Enalapril is the third generation of angiotensin converting enzyme inhibitor (ACEI). It plays an important role in safe and effective anti-hypertension, reversing ventricular hypertrophy, ventricular remodeling and other cardiovascular diseases. As an ACEI drug, it is hydrolyzed into enalapril in vivo after oral administration, which has a strong inhibitory effect on angiotensin converting enzyme. Thus, it can inhibit the proliferation of myocardial fibers and cells, inhibit the apoptosis of myocardial cells, inhibit the influx of calcium ions in myocardial cells, inhibit heart rate remodeling, and then control heart failure, At the same time, it can inhibit the activity of renin angiotensin system (RAS) in myocardial tissue, reduce the formation of vasoactive angiotensin II, improve left ventricular diastolic function to reduce blood pressure and treat hypertension.


Product Use:


Angiotensin converting enzyme inhibitor, is the world's second ACE-I after captopril. The effect on high blood pressure is similar to, but stronger than, captopril, and the effect is slow and long-lasting. As with Captopril, combination with diuretic dihydrochlorothiazide generally improves efficacy by 15 to 30 percent.


Cas 75847-73-3 Antihypertensive Drug Enalapril For High Blood Pressure ACE Inhibitors Powder 0Cas 75847-73-3 Antihypertensive Drug Enalapril For High Blood Pressure ACE Inhibitors Powder 1

Product Catalogue:


Number Cas Name
1 41859-67-0 Bezafibrate
2 62571-86-2 Captopril
3 113665-84-2 Clopidogrel
4 75847-73-3 Enalapril
5 49562-28-9 Fenofibrate
6 25812-30-0 Gemfibrozil
7 21187-98-4 Glicalzide
8 138402-11-6 Irbesartan
9 83915-83-7 Lisinopril
10 75330-75-5 Lovastatin
11 79902-63-9 Simvastatin
12 87333-19-5 Ramipril
13 144701-48-4 Telmisartan
14 13649-88-2 Deflazacort
15 50-02-2 Dexamethasone
16 2135-17-3 Flumethasone
17 53-03-2 Prednisone



About us



Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.

In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.

In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.


Contact Details
William Wang

Phone Number : +86-13588430486

WhatsApp : +8613588430486